Yellow Fever Vaccine

Identification

Name
Yellow Fever Vaccine
Accession Number
DB10805  (DB14448)
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Description

Yellow Fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a flavivirus through the bite of an infected mosquito. Symptoms of Yellow Fever can range from asymptomatic, to mild flu-like illness, to more severe symptoms such as shock, jaundice, internal bleeding, and organ failure [4]. Interestingly, Yellow Fever got its name from the characteristic yellowing of the skin and eyes that occurs from the development of jaundice when the virus attacks the liver. Although there is supportive treatment available for managing Yellow Fever, there are currently no antivirals developed to specifically treat Yellow Fever. Vaccination with Yellow Fever vaccine is therefore considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days [Label]. The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease" [3].

Yellow Fever is most commonly found in the southern hemisphere, in tropical regions of Africa and Central/South America [2]. The World Health Organization recommends routine vaccination in countries where Yellow Fever is endemic, and for travellers going to endemic areas as proof of vaccination is often a requirement at border crossings to prevent international spread of the disease [2, 5].

Yellow Fever Vaccine is a subcutaneously administered vaccination for the active immunization and prophylaxis of yellow fever in pediatric patients 9 months of age and older. It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [Label]. The FDA recommends vaccination with Yellow Fever Vaccine for persons living in or travelling to endemic areas and for laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus.

Synonyms
  • Flavivirus yellow fever virus 17D-204 whole
  • Yellow fever virus 17D/tiantan live antigen
  • Yellow fever virus live antigen, A
  • Yellow fever virus strain 17D (live, attenuated)
  • Yellow fever virus strain 17D-204 live (attenuated) antigen
  • Yellow fever virus strain 17D-204 live antigen
  • Yellow fever, live attenuated
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Yf-vaxInjection, powder, lyophilized, for suspension4.74 [PFU]/0.5mLSubcutaneousSanofi Pasteur Limited1953-05-22Not applicableUs
Yf-vax (yellow Fever Vaccine)Powder, for solution109648 pfuSubcutaneousSanofi Pasteur Limited1978-12-31Not applicableCanada
Categories
UNII
PY4EET359T
CAS number
Not Available

Pharmacology

Indication

Yellow Fever Vaccine is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories:

  1. Persons Living in or Traveling to Endemic Areas: While the actual risk for contracting yellow fever during travel is probably low, variability of itineraries, behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area. Greater risk is associated with living in or traveling to areas of South America and Africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone.

  2. Persons Travelling Internationally Through Countries with Yellow Fever: Some countries require an individual to have a valid International Certificate of Vaccination or Prophylaxis (ICVP) if the individual has been in countries either known or thought to harbor yellow fever virus. The certificate becomes valid 10 days after vaccination with Yellow Fever Vaccine.

  3. Laboratory Personnel: Laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect contact or by aerosols.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Yellow Fever Vaccine is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [Label]. Vaccination with Yellow Fever vaccine is considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days [Label].

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Yellow Fever Vaccine.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Yellow Fever Vaccine.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Yellow Fever Vaccine.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Yellow Fever Vaccine.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Yellow Fever Vaccine.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Yellow Fever Vaccine.
AbituzumabThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Yellow Fever Vaccine.
AdalimumabThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Adalimumab.
AdalimumabThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Adalimumab.
Food Interactions
Not Available

References

General References
  1. Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhaes V, Costa-Pereira C, Albuquerque CP, Muniz LF, Yokoy de Souza T, Oliveira ACV, Martins-Filho OA, da Mota LMH: The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Rev Vaccines. 2018 Jan;17(1):79-90. doi: 10.1080/14760584.2018.1406800. Epub 2017 Nov 27. [PubMed:29172832]
  2. World Health Organization - Yellow Fever Fact Sheet [Link]
  3. World Health Organization - Yellow fever vaccination booster not needed [Link]
  4. CDC - Yellow Fever Symptoms and Treatment [Link]
  5. CDC - Yellow Fever Vaccine [Link]
External Links
PubChem Substance
347910911
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Yellow_fever_vaccine
AHFS Codes
  • 80:12.00 — Vaccines
FDA label
Download (246 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedNot AvailableEncephalitis, Japanese B / Yellow Fever1
2CompletedPreventionMalaria Vaccines / Plasmodium Infections1
3Active Not RecruitingPreventionPlasmodium Infections1
3CompletedPreventionDengue Fever / Dengue Hemorrhagic Fever / Yellow Fever1
3CompletedPreventionEncephalitis, Japanese B / Meningococcal Disease / Meningococcal Meningitis / Rabies / Salmonella Typhi Infection / Yellow Fever1
4Active Not RecruitingPreventionImmunity / Yellow Fever Vaccine1
4CompletedTreatmentDiarrhea Rotavirus1
Not AvailableActive Not RecruitingBasic ScienceYellow Fever2
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableRecruitingNot AvailableHealthy Volunteers1
Not AvailableRecruitingPreventionGranulomatosis With Polyangiitis / Inflammatory Myopathy / Juvenile Dermatomyositis / Juvenile Idiopathic Arthritis (JIA) / Mixed Connective Tissue Disease (MCTD) / Rheumatoid Arthritis / Sclerosis, Progressive Systemic / Sjögren's Syndrome / Spondyloarthritis / Systemic Lupus / Takayasu's Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionSubcutaneous4.74 [PFU]/0.5mL
Powder, for solutionSubcutaneous109648 pfu
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on October 16, 2018 08:42